GNI Group

2160.TSE

15.80 USD

-0.53

-3.25%

Overview

Last close

15.80 usd

Market cap

878.62M usd

52 week high

30.23 usd

52 week low

10.22 usd

Target price

27.38 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

5.3316

Price/Book Value

2.7881

Enterprise Value

726.38M usd

EV/Revenue

4.7276

EV/EBITDA

278.0341

Key financials

Revenue TTM

164.13M usd

Gross Profit TTM

119.29M usd

EBITDA TTM

-1.82M usd

Earnings per Share

-0.02 usd

Dividend

N/A usd

Total assets

558.65M usd

Net debt

-120.42M usd

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573, which is in phase II for the treatment of acute chronic liver failure. Further, it is developing F528, which is in Phase 2 clinical trial for Chronic Obstructive Pulmonary Disease; and F230, which is in clinical trial for Pulmonary Arterial Hypertension. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.